



INTERNATIONAL FEDERATION  
OF PSORIASIS ASSOCIATIONS

# **ANNUAL ACCOUNTS**

**For**



**INTERNATIONAL FEDERATION  
OF PSORIASIS ASSOCIATIONS**

**ORG. NO  
802428-5986**

**THE FINANCIAL YEAR  
2017**





## **Director's Declaration**

### **Purpose**

The purposes for which the Federation is formed are to advance efforts to lessen the suffering of people with psoriasis and to improve methods of treatment and research for finding the ultimate cause and cure of the disease. In order to realize its purposes, the Federation shall:

- a) Represent the interests of its member associations in international forums such as the World Health Organization, the World Congress of Dermatology and international psoriasis symposia. IFPA shall also in close cooperation with other relevant international organizations organize international conferences, symposia and other events related to psoriasis/psoriatic arthritis, e.g. The World Psoriasis Day.
- b) Provide advice and consultation on the problems associated with psoriasis to member organizations or other communities and organizations worldwide.
- c) Provide the basis for closer liaison and the free exchange of information among psoriasis organizations and related organizations worldwide.
- d) Encourage and assist the establishment of new national organizations of people with psoriasis.
- e) Contribute to the improvement of the quality of health and social life of people suffering from psoriasis and psoriatic arthritis.
- f) The Federation shall not supersede or contravene the autonomy of national or other member organizations.

### **Vision**

Achieve a world without suffering from psoriasis.

### **Mission**

Be the global psoriasis advocacy association, with a focus on empowering our members, improving living conditions for psoriasis patients, raising awareness and cooperating with fellow stakeholders.



## **Goals**

IFPA's goals as an organization are to:

1. Empower national psoriasis organizations by uniting them, strengthening their work and acting as their global voice.
2. Improve patients' living conditions by advocating for correct diagnosis, universal access to treatment and less discrimination and stigmatization.
3. Raise psoriasis awareness through education, information and highlighting research results.
4. Cooperate with relevant psoriasis stakeholders, including medical and pharmaceutical actors.

## **Governance**

IFPA is governed by the General Assembly (GA) of its Full members. The meeting of the General Assembly is held every three years, with the next to be held in 2019. According to the General Assembly's decision in June 2016, a structural change in IFPA was approved, meaning that IFPA has now a Board and not an Executive Committee anymore and that the Secretariat is now led by an Executive Director.

In furtherance of the objectives of the Federation, the IFPA Board shall implement IFPA policies and management between official General Assembly meetings. The IFPA Board may also call an Extraordinary General Assembly meeting, either as a physical meeting or by postal/online vote, should any urgent amendments to or clarifications of the IFPA Constitution or Bylaws be deemed necessary. In 2017 the IFPA Board had five meetings, of which three physical and two telemeetings.

## **IFPA Secretariat**

In order to assist the IFPA Board in its management of the Federation and its projects, a Secretariat was formed in 2007, and placed in Stockholm, Sweden. As per 2016 IFPA took over the employer liability from the Swedish Psoriasis Association, and runs the organization independently.

IFPA decided to move its office to new premises in Alvik Strand, Stockholm, which suited the organization's needs and requirements. During 2017 the IFPA Secretariat has been comprised of four staff members - an Executive Director, a Communications Manager, a Policy and Advocacy Officer, and Manager Administration and Events. Additionally, a Scientific Officer was employed in late December.



INTERNATIONAL FEDERATION  
OF PSORIASIS ASSOCIATIONS

3 (18)

### **Main activities 2017**

- IFPA Advocacy project – Global Psoriasis Coalition
- World Psoriasis Day
- 5th World Psoriasis & Psoriatic Arthritis Conference 2018
- IFPA Member meeting
- Global Psoriasis Atlas
- Fundraising - IFPA Solidarity Fund

### **IFPA Advocacy project – Global Psoriasis Coalition (UN/WHO)**

- Global, regional and national recognition for psoriasis as a chronic, serious non-communicable and disabling disease steps into its next phase as the WHO psoriasis resolution was adopted at the 67th World Health Assembly in May 2014.
- In early 2016, the WHO published a Global report on psoriasis, with contribution from IFPA and its members. This was a true milestone for the psoriasis community as this was WHO's first report on psoriasis. The report on psoriasis brings the public health impact on psoriasis into focus and highlights recommended actions for governments and policy-makers to control and prevent its complications.
- Ensuring psoriasis steadily emerges as a global health issue requires coordinated and cross-sectoral action. In the light of this, IFPA initiated the Global Psoriasis Coalition project to continue meeting the needs of people with psoriasis worldwide. Following up to the Report, the Global Psoriasis Coalition aims to answer several key issues included in the Report, thus boosting rights-based global and local advocacy. The mission with the Global Psoriasis coalition is to act as the recognized, multi-stakeholder advocate for the improvement the living conditions of people with psoriasis. The Coalition's overarching objective is to promote psoriasis in the non-communicable diseases policy agenda in the period 2018-2020, with reference to the scheduled revision of the NCD Action Plan for 2018, and consequently 2020.



4 (18)

The IFPA Advocacy project 2017 focused mainly on the Global Psoriasis Coalition Project (the implementation of the WHO psoriasis resolution and the recommendations of the WHO global report). Strengthening IFPA's role and position within the global disability movement and develop IFPA's strategic work within the Human Rights field, focusing on the stigmatization and discrimination aspects related to psoriasis, was not prioritized due to IFPA's re-organization and scarce personnel resources. Three main objectives were set during 2017:

- Increase the level of understanding, motivate behavior change and raise the global acceptance of the disease.
- Align stakeholders with diverse constituencies around/on a shared action framework to manage psoriasis.
- Foster new cross-sectoral partnerships.



INTERNATIONAL FEDERATION  
OF PSORIASIS ASSOCIATIONS

5(18)

Outcome	Activities type	Results September 2017
<ul style="list-style-type: none"> <li>• Create an information hub / go-to place on psoriasis</li> <li>• Promote psoriasis as a chronic, non-communicable disease</li> <li>• Pull WHO Resolution incl. WHO report and other international instrument</li> <li>• Identifying and seizing up on advocacy opportunities for advancing the agenda on psoriasis</li> </ul>	<ul style="list-style-type: none"> <li>1.1 Conceive Coalition identity</li> <li>1.2 Conceive Coalition website</li> <li>1.3 Pull together Coalition Partners resources on psoriasis</li> <li>1.4 Develop a public affairs plan to approach governments and int'l organizations</li> <li>1.5 Ongoing strategic support to IFPA in achieving objective #1</li> <li>1.6 Advocacy Calendar</li> <li>1.7 Landscape Analysis of new potential partners</li> <li>1.8. Economic burden analysis (if funding available)</li> </ul>	<ul style="list-style-type: none"> <li>1.1. Coalition's logo and slogan were developed and promoted for use</li> <li>1.2. A Coalition section within IFPA's website was developed</li> <li>1.3. Resource plan, activity plan and budgets were developed and used in the further work by IFPA and HLG</li> <li>1.4. Public affairs activities were communicated during partner meetings, but not formalized in a public affairs plan</li> <li>1.5. Non-formal methods of monitoring and evaluation of the work were put in place</li> <li>1.6. Advocacy Calendar and Key Activities 2017 list were developed and communicated</li> <li>1.7. Following the carried-out landscape analysis, potential sectors and partner profiles were identified and will be presented on the meeting in September 2017</li> <li>1.8. Materials and social media plan were produced ahead of all events where the Coalition participated.</li> </ul>
<ul style="list-style-type: none"> <li>• Coalition joint statement</li> <li>• Refine and/or develop new policy messages</li> <li>• Conduct joint communications</li> </ul>	<ul style="list-style-type: none"> <li>1.8 Draft an Action Framework</li> <li>1.9 Finalize TORs</li> <li>1.10 Produce a set of one or two pagers including messages tailored to</li> </ul>	<ul style="list-style-type: none"> <li>2.1. The Coalition's Strategy was finalized and communicated, while actions were communicated over online partner meetings</li> </ul>



INTERNATIONAL FEDERATION  
OF PSORIASIS ASSOCIATIONS

6(18)

Outcome	Activities type	Results September 2017
	<p>different Coalition's constituencies</p> <p>1.11 Communications plan and support (incl. digital)</p> <p>1.12 Ongoing strategic support to IFPA in achieving objective #2</p>	<p>2.2. ToRs were finalized and communicated, as part of the Coalition's Strategy</p> <p>2.3. Set of social media messages and an explanation of the event, goals and outcomes have been prepared for all events listed under 3.</p> <p>2.4. Communications guidelines were produced, as part of the Coalition Toolkit</p> <p>2.5. Non-formal methods of monitoring and evaluation of the work were put in place</p>
<ul style="list-style-type: none"> <li>• Execute advocacy events at global and regional levels</li> <li>• Initiate regional collaboration programs for IFPA Members</li> <li>• Encourage cooperation with partners from other related medical fields</li> </ul>	<p>2.1 Ongoing strategic support to IFPA to achieving objective #3</p> <p>2.2 140<sup>th</sup> Session of the WHO Executive Board, January, Geneva</p> <p>2.3 Startup meeting at AAD, Orlando, including support package (panel setup, policy alignment, comms pre- and post-)</p> <p>2.4 Participation in ICD, Buenos Aires and a first start up meeting in the region (includes support for preparation)</p> <p>2.5 Side event at WHA, Geneva, (includes support for preparation)</p> <p>2.6 Side event at AFRO Regional Committee, Africa, (includes support for preparation)</p> <p>2.7 Side event at EADV, Geneva, September 2017 (includes support for preparation)</p> <p>2.8 Side event at NCDA Global Forum, Sharjah</p>	<p>3.1. Non-formal methods of monitoring and evaluation of the work were put in place</p> <p>3.2. A mapping of relevant missions was carried out and initial communication was established with 15 Permanent Missions. All the meetings were carried out in a positive tone, the final support for the external side event during the WHA was given by 5 Permanent Missions. The discussions on NCDs were actively followed during the 140<sup>th</sup> Session of the WHO Executive Board</p> <p>3.3. A start up meeting was organized during the AAD with stakeholders onsite to discuss further the main idea and rationale behind the Coalition. Social media messages were produced</p> <p>3.4. In the margins of ICD, a side event on the Coalition was organized, together with a meeting with the regional</p>



INTERNATIONAL FEDERATION  
OF PSORIASIS ASSOCIATIONS

7(18)

Outcome	Activities type	Results September 2017
	<p>2.9 Any other event proposed by Coalition Members</p>	<p>representatives from Latin America aimed to introduce the concept of the Coalition and motivate regional activity</p> <p>3.5. An external side event, supported by Argentina, Ecuador, Panama, Philippines and Qatar was organized. The side event was attended by over 60 participants, and welcome speeches were carried out by high government officials from Panama, Argentina and Ecuador.</p> <p>3.6. The side event was carried out in partnership with the WHO AFRO Office. The attendance was reserved to high-level officials only.</p> <p>3.7. Due to a changed concept of the EADV, there was no possibility to carry out a Coalition side event. Instead, a Coalition meeting including the Steering Committee and Reference group is organized on the margins of the EADV.</p> <p>3.8. The side event for Sharjah is in process of development.</p> <p>3.9. Additional events identified by the Coalition are the WHO Global NCD Conference, 10<sup>th</sup> European Public Health Conference, and the European Health Forum Gastein, for which further plans are to be developed.</p>



INTERNATIONAL FEDERATION  
OF PSORIASIS ASSOCIATIONS

8(18)

### **External meetings**

IFPA was represented at several meetings, summits and conferences organized by the WHO as well as IFPA's regional members and partner meetings. Examples of activities:

- AAD Annual Meeting, Feb, Orlando, USA
- World Health Assembly, May, Geneva, Switzerland
- U.N. High Level Political Forum 2017, June 11-12th, New York, USA
- Civil Society CRPD Forum June 12-15th, New York, USA
- EADV Congress, Sept 13-17, Geneva, Switzerland
- Global NCD Alliance Forum 2017 – Stepping up the pace on NCDs: Making 2018 count – December 9-11th 2017, Sharjah, UAE

### **World Psoriasis Day 2017**

The theme for World Psoriasis Day 2017 was: "Psoriasis Inside Out", focusing on showing all aspects of the disease and to give a face to pso/psa and to share stories. For that reason, IFPA and its members in 56 countries are organizing awareness-raising and advocacy campaigns to improve access to treatment, increase understanding and build unity among the psoriasis community.

### **Core communication messages**

#### **PSOMANYSIDES**

Psoriasis is so much more than psoriasis and psoriatic arthritis. In the spirit of the Global Psoriasis Coalition initiated by IFPA late 2016, the message was to raise all the aspects of the disease (including NCDs comorbidities) during the year.

#### **PSOME**

There is a person (not only a patient) living daily with psoriasis and psoriatic arthritis, facing challenges and suffering from the impacts of the disease. This theme aimed to showcase the stories of the persons living with pso/psa and let them describe how it impacts their daily life (sharing challenges as well as successes). The stories were aimed at providing support and attention for the campaign.



INTERNATIONAL FEDERATION  
OF PSORIASIS ASSOCIATIONS

9(18)

### Objectives

- Giving a clear picture of psoriasis and psoriatic arthritis.
- Making people understand that Pso/Psa is much more than just the psoriatic disease and to focus on NCD co-morbidities
- Showing that there is a person behind the disease that suffers daily from multiple conditions
- Raising awareness about Pso/Psa having a major impact on the patients and their families.

A wide range of World Psoriasis Day awareness-raising activities were carried out by IFPA's members all over the globe, from seminars to meetings with politicians and decision makers. Every year IFPA sees an increased interest in World Psoriasis Day and awareness raising activities taking place.

### **The 5th World Psoriasis & Psoriatic Arthritis Conference 2018**

In 2016 IFPA started the planning and preparation process for the World Psoriasis & Psoriatic Arthritis Conference, to be held in Stockholm in 2018. Its theme is: "Psoriasis – Science and Patients: Global Challenges and Future perspectives". Professor Mona Ståhle from Karolinska University Hospital, Sweden has been assigned as President of the upcoming conference.

The conference has been promoted extensively throughout the year, at various conference and events, where IFPA being represented all the way until the start of the conference.

IFPA, together with the congress bureau MeetAgain, who was given the assignment as the PCO, professional conference organizer, initiated the conference project plan and timeline to be followed up until the execution of the conference. This has been to ensure that the conference meets the quality standards expected from international target groups and audiences within this field.

Just as with the previous conferences, IFPA's members were given the opportunity to suggest topics/issues that are felt to be highly relevant for the psoriasis community – be it locally, nationally, regionally or globally. Their suggestions were forwarded to the Scientific Executive Committee, as well as the Organizing Committee, for their respective evaluation and topics might be included in the conference programs.



### **IFPA Member meeting**

In June, IFPA had the great pleasure of welcoming the IFPA members to Brussels, Belgium, for two full days of workshops and seminars. The event had strong attendance with the participation of more than 50 national and regional associations, IFPA Board and Secretariat, as well as IFPA's partners. The meeting opened with a welcome speech by Lars Ettarp, IFPA President, followed by the presentation of the Financial report by Josef de Guzman, IFPA's Treasurer. Subsequently, Hoseah Waweru, IFPA Vice-president reported on the preparations for the World Psoriasis and Psoriatic Arthritis Conference in 2018.

The first day of the meeting also contained an advocacy workshop led by Vasilka Lalevska, IFPA's Policy and Advocacy Officer, who updated the attendants on IFPA's achievements in global advocacy, and a workshop on grant applications by Sophie Andersson, IFPA's Executive Director. Thereafter, IFPA's Board Member and Secretary Silvia Fernandez Barrio reported on IFPA's regional development and new members and introduced new presidents of IFPA's regional members, namely Paul Mendoza of PSORASIA, Gustavo di Genio of LATINAPSO, and Jan Koren of EUROPSO. During the first day, national associations had a chance to showcase the activities and achievements and share success stories with the IFPA family and network with other members.

The second day of the members' meeting focused on a capacity development session for member associations covering the subject of organisational development. The members also got acquainted with the World Psoriasis Day 2016 report and the theme and activities planned within the World Psoriasis Day on 29 October 2017. The World Psoriasis Day 2017 main theme was "Psoriasis Inside Out", focusing on the fact that psoriasis is so much more than what is seen on the outside whilst psoriasis patients are, for example, at increased risk to develop so-called comorbidities. On this occasion, IFPA has developed a series of branded collaterals, theme and messages, to unveil the stories of the persons living with psoriasis and psoriatic arthritis and let them describe how it impacts their daily life. The second day of the meeting also provided a chance for member associations to meet with IFPA partners and share patient perspectives and needs. The meeting was concluded by closing remarks by Lars Ettarp, who also announced that the next IFPA members meeting will take place in Stockholm, Sweden, in June 2018.

### **Members**

On December 31<sup>st</sup>, 2017, IFPA had fifty-six Full member organizations and one Associated member organization. Two new members joined IFPA during 2017: The Dominican Republic and Uruguay.



### **Memberships**

IFPA became a member of the Global Health Council in 2017 and has been a member of the NCD Alliance since 2016. IFPA is a Full member of the International Alliance of Patients' Organizations (IAPO) since 2012 and a member of the Noncommunicable Diseases Alliance Common Interest Group since 2011.

### **The Global Psoriasis Atlas**

The Board of Governors, IFPA, the International League of Dermatological Societies (ILDS) and the International Psoriasis Council (IPC), initiated the Global Psoriasis Atlas, GPA, in 2015 and have continuously worked with the structure of the project including legal entities, academic institution alignment, contractive and flow and indicative budgets. Workstreams have been developed with mission to focus on:

- Workstream 1: conduct systematic review of current available literature with the desired outcome of a publication in suitable high impact journals
- Workstream 2: determine a methodology to serve the framework for compiling the Global Psoriasis Atlas, thus providing a standard operating procedure to execute the GPA under a "hub and spoke" model

The project was launched on September 28th 2016 at the EADV Conference, in Vienna, one of the largest European Congresses in Dermatology and Venereology. It was communicated that the GPA is now a reality and that the consortium is a functioning entity working on the planning of the project. The first phase of the project started in 2017 and has the focus on gathering the existing data about psoriasis mostly in Europe and USA.

Project funding was confirmed from several partners, ensuring partial project financial stability. A collaboration agreement and other documents were drafted to determine the roles and responsibilities of respective party. Future key actions will be to decide on the position of Programme Director, find solution to be found regarding some potential funding for the administrative work/support of IFPA.

### **Corporate Partners**

In 2017 IFPA received project support from the following corporate partners: AbbVie, Celgene, LEO Pharma, Eli Lilly, Novartis, Pfizer and SunPharma/Almirall.

IFPA was also represented at several meetings hosted by the corporate partners. IFPA had the opportunity to present its work with special emphasis on advocacy as well as influencing the agenda and present the global voice of the patients.



### **Fundraising / IFPA Solidarity Fund**

In the autumn of 2016, IFPA launched the IFPA Solidarity Fund, a new project aimed to address the everyday funding gap IFPA's members face, and to award grants to support psoriasis advocacy, education and awareness-raising. The IFPA Solidarity Fund was set up through voluntary contributions by IFPA supporters, IFPA members and other actors. A first application call was sent out and IFPA to grant small-scale projects up to 1500 EUR per project in early 2017.

### **Administration report**

The Board of the International Federation of Psoriasis Associations (IFPA) hereby delivers the annual account for the financial year 2017-01-01 - 2017-12-31.

#### *Accounting and valuation principles*

The annual account has been prepared in accordance with the Swedish Accounting Act.

Regarding the results and financial position, please refer to the attached financial statements and accompanying notes.



INTERNATIONAL FEDERATION  
OF PSORIASIS ASSOCIATIONS

13 (18)

## International Federation of Psoriasis Associations (IFPA)

Org. no 802428-5986

Profit and loss account	2017-01-01		2016-01-01	
	2017-12-31	EUR	2016-12-31	EUR
	SEK	9,8497	SEK	9,4704
<b>Income</b>				
Membership fees	69 115	7 017	77 697	8 204
Donations	185 916	18 875	0	0
Rounding- off to whole kronor	-5	0	6	1
Amount WPC	75 976	7 714	904 655	95 524
Participation fees	7 653	777	66 258	6 996
Refunds and reimbursement	23 944	2 431	540 432	57 065
Jansen Cilag	0	0	323 284	34 136
AbbVie	614 114	62 348	834 588	88 126
Almirall S.A.	566 874	57 552	0	0
Sun Pharmaceutical Industries Inc.	564 154	57 276	0	0
LED Pharma A/S	915 146	92 911	599 456	63 298
Celgene	1201538	121987	620 984	65571
Novartis	897 551	91125	1004 741	106 093
Eli Lilly	1 155 116	117 274	600 457	63 404
Pfizer	611800	62 114	334 842	35 357
Other operating income	711975	72 284	-	-
<b>Total income</b>	<b>7 600 864</b>	<b>771 685</b>	<b>5 907 399</b>	<b>623 775</b>
<b>Costs</b>				
Outgoing donations	-168 966	-17 154	0	0
Office rental agreement	-342 044	-34 726	-394 886	-41697
Freight and transport	-13 710	-1392	-2 655	-280
Conference costs	-291636	-29 609	-167 963	-17 736
Telemeetings	-10 733	-1090	-6 697	-707
Travel costs	-558 573	-56 710	-362 594	-38 287
Refund members	-164 935	-16 745	-187 855	-19 836
Hotel costs	-317 697	-32 255	-240 825	-25 429
Food	-92 509	-9 392	-82 019	-8 661
Reimbursement	-107 773	-10 942	-44 455	-4 694
Printing costs	-98 678	-10 018	-56 289	-5 944
PR-Marketing	-293 660	-29 814	-9 979	-1054
Gifts	-9 309	-945	-2 288	-242
Office material	-73 062	-7 418	-80 806	-8 533
Phone	-40 721	-4 134	-28 960	-3 058
Insurance for the organisation	-9 658	-981	-6 741	-712
Losses on receivables	3 500	355	-9 560	-1009
Accountant and audit	-233 518	-23 708	-299 123	-31585
Consultants	-1589 712	-161397	-381 339	-40 266
Web	-162 068	-16 454	-173 886	-18 361
Newsservice	-49 500	-5 026	-68 550	-7 238
Bank fees	-24 100	-2 447	-14 912	-1575
Wire transaction fees	-255	-26	0	0
Membership fees	-302 391	-30 701	-5 843	-617
Subscriptions and articles	-9 772	-992	0	0
Other operating expenses	-239 216	-24 287	0	0
Interest income tax account	-7	-1	11	1
Interest taxes and fees	-10 131	-1029	-100	-11
Staff costs	-2 315 031	-235 036	-2 191 094	-231362
Cost of interest	0	0	0	0
Exchange profit/loss	-46 057	-4 676	18 065	1 908
<b>Total costs</b>	<b>-7 571 925</b>	<b>-768 747</b>	<b>-4 801 343</b>	<b>-506 984</b>
<b>Profit (+) / Loss (-)</b>	<b>28 939</b>	<b>2 938</b>	<b>1 106 056</b>	<b>116 791</b>



INTERNATIONAL FEDERATION  
OF PSORIASIS ASSOCIATIONS

14 (18)

### 1. WPC

Freight and transport	-1463	-149	0	0
Conference costs	-93 507	-9 493	0	0
Travel costs	-51 367	-5 215	0	0
Hotel costs	-8 226	-835	0	0
Food	-250	-25	0	0
Reimbursement	-8 020	-814	0	0
Printing costs	-44 143	-4 482	-2 275	-240
PR-Marketing	-186 977	-18 983	0	0
Consultants	-100 000	-10 153	0	0
Web	0	0	-1 098	-116
Exchange profit/ loss	12 384	1 257	0	0
Other operating expenses	-239 216	-24 287	0	0
<b>Total costs</b>	<b>-720 786</b>	<b>-73 178</b>	<b>-3 373</b>	<b>-356</b>

### 2. World Psoriasis Day

Freight and transport	-2 478	-252	0	0
Conference costs	-112 992	-11 472	-130 035	-13 731
Travel costs	-149 927	-15 222	-100 626	-10 625
Refund members	-164 935	-16 745	-183 685	-19 396
Hotel costs	-186 650	-18 950	-96 652	-10 206
Food	-41 295	-4 193	-40 243	-4 249
Reimbursement	-8 051	-817	-817	-86
Printing costs	-1 699	-172	-12 771	-1 349
PR-Marketing	-26 633	-2 704	0	0
Gifts	-1 153	-117	-1 288	-136
Office material	0	0	-360	-38
Consultants	-181 641	-18 441	-28 125	-2 970
Bank fee	-193	-20	0	0
Losses on receivables	4 144	421	-9 560	-1 009
Exchange profit/ loss	-257	-26	-44	-5
<b>Total costs</b>	<b>-873 762</b>	<b>-88 710</b>	<b>-604 205</b>	<b>-63 799</b>

### 4. EADV

Conference costs	-6 385	-648	-23 919	-2 526
Travel costs	-24 966	-2 535	-16 697	-1 763
Hotel costs	-2 336	-237	-24 702	-2 608
Reimbursement	-13 967	-1 418	-5 320	-562
Printing costs	0	0	0	0
<b>Total costs</b>	<b>-47 654</b>	<b>-4 838</b>	<b>-70 637</b>	<b>-7 459</b>

### Costs per activity

	2017-01-01 2017-12-31		2016-01-01 2016-12-31	
	SEK	EUR	SEK	EUR
		9,8497		9,4704

### 5. External Meetings

Conference costs	0	0	-7 158	-756
Travel costs	-17 856	-1 813	-58 120	-6 137
Hotel costs	-991	-101	-45 633	-4 818
Food	-214	-22	-1 718	-181
Reimbursement	-14 513	-1 473	-3 740	-395
PR-Marketing	0	0	-4 977	-526
<b>Total costs</b>	<b>-33 575</b>	<b>-3 409</b>	<b>-121 345</b>	<b>-12 813</b>

### 6. EC Meetings

Freight and transport	0	0	-609	-64
Conference costs	-20 727	-2 104	-3 403	-359
Telemeetings	0	0	-1 899	-201
Travel costs	-110 396	-11 208	-109 194	-11 530
Hotel costs	-35 780	-3 633	-33 060	-3 491
Food	-17 041	-1 730	-27 371	-2 890
Reimbursement	-41 914	-4 255	-16 754	-1 769
Web	0	0	-6 885	-727
Wire transaction fees	-127	-13	0	0
<b>Total costs</b>	<b>-225 984</b>	<b>-22 943</b>	<b>-199 175</b>	<b>-21 031</b>



INTERNATIONAL FEDERATION  
OF PSORIASIS ASSOCIATIONS

15 (18)

<b>7. Psoriasis Atlas</b>				
Consultants	0	0	-8 807	-930
<b>Total costs</b>	<b>0</b>	<b>0</b>	<b>-8 807</b>	<b>-930</b>
<b>8. Advocacy</b>				
Conference costs	0	0	-1450	-153
Travel costs	-15 667	-1591	-57 136	-6 033
Hotel costs	-3 285	-334	-38 079	-4 021
Food	0	0	-4 942	-522
Reimbursement	0	0	-17 425	-1840
Printing costs	0	0	-30 107	-3 179
Office material	0	0	-420	-44
Consultants	0	0	-69 085	-7 295
Bank fees	0	0	-120	-13
<b>Total costs</b>	<b>-18 952</b>	<b>-1 924</b>	<b>-218 764</b>	<b>-23 100</b>
<b>9. Under the Spotlight</b>				
Web	-4 656	-473	-30 963	-3 269
<b>Total costs</b>	<b>-4 656</b>	<b>-473</b>	<b>-30 963</b>	<b>-3 269</b>
<b>Costs per activity</b>				
	2017-01-01		2016-01-01	
	2017-12-31		2016-12-31	
	SEK	EUR	SEK	EUR
		9,8497		9,4704
<b>10. IFPA</b>				
Office rental agreement	-342 044	-34 726	-394 886	-41 697
Freight and transport	-3 423	-347	-2 046	-216
Conference costs	-8 353	-848	-1 998	-211
Telemeetings	-10 032	-1 018	-4 797	-507
Travel costs	-7 632	-775	-20 823	-2 199
Refund members	0	0	-4 169	-440
Hotel costs	-337	-34	-2 700	-285
Food	-14 245	-1 446	-7 745	-818
Reimbursement	-15 21	-154	-399	-42
Printing costs	-9 676	-982	-11 136	-1 176
PR-Marketing	-21 001	-2 132	-5 002	-528
Gifts	-8 156	-828	-1 000	-106
Office material	-61 878	-6 282	-80 026	-8 450
Phone	-40 721	-4 134	-28 960	-3 058
Insurance for the organisation	-9 658	-981	-6 741	-712
Accountant and audit	-233 518	-23 708	-299 123	-31 585
Consultants	-178 469	-18 119	-147 675	-15 593
Web	-157 412	-15 981	-134 939	-14 249
Newsservice	-49 500	-5 026	-68 550	-7 238
Bank fees	-23 728	-2 409	-14 792	-1 562
Wire transaction fees	0	0	0	0
Membership fees	-73 689	-7 481	-5 843	-617
Subscription and articles	-9 772	-992	0	0
Salary costs	-2 315 031	-235 036	-2 191 094	-231 362
Losses on receivables	-644	-65	0	0
Interest income tax account	-7	-1	11	1
Interest expenses for taxes and	-10 131	-1 029	-100	-11
Exchange profit/loss	-14 140	-1 436	18 108	1 912
<b>Total costs</b>	<b>-3 604 717</b>	<b>-365 972</b>	<b>-3 416 427</b>	<b>-360 748</b>



INTERNATIONAL FEDERATION  
OF PSORIASIS ASSOCIATIONS

16 (18)

## 12. IFPA Solidarity Fund

Outgoing donations	-72 303	-7 341	0	0
<b>Total costs</b>	<b>-72 303</b>	<b>-7 341</b>	<b>0</b>	<b>0</b>

## 13. Global Psoriasis Coalition

Outgoing donations	-96 663	-9 814	0	0
Freight and transport	-6 347	-644	0	0
Conference costs	-49 669	-5 043	0	0
Telemeetings	-701	-71	0	0
Travel costs	-180 762	-18 352	0	0
Hotel costs	-80 092	-8 131	0	0
Food	-19 464	-1 976	0	0
Reimbursement	-19 786	-2 009	0	0
Printing costs	-43 161	-4 382	0	0
PR-Marketing	-59 050	-5 995	0	0
Office material	-11 184	-1 135	0	0
Consultants	-1 129 601	-114 684	-127 646	-13 478
Bank fees	-178	-18	0	0
Wire transaction fees	-128	-13	0	0
Membership fees	-228 703	-23 219	0	0
Exchange profit/loss	-44 044	-4 472	0	0
<b>Total costs</b>	<b>-1 969 532</b>	<b>-199 959</b>	<b>-127 646</b>	<b>-13 478</b>

These cost centers didn't have any costs year 2017 and 2016:

11. Africa project

These cost centers weren't used during year 2016 and during year 2017 they were deleted:

3. Social Media Projects

Balance sheet		2017-01-01		2016-01-01	
		2017-12-31		2016-12-31	
		SEK	EUR	SEK	EUR
<b>Bank assets and claims</b>	<b>Not</b>		9,8497		9,5663
Outstanding claims	1	8 428	856	1 905 029	199 127
Other claims		14	1	2	0
Prepaid expenses and accrued	2	388 647	39 458	406 226	42 462
Cash		2 367	240	6 381	667
Bank Nordea		6 972 009	707 840	5 983 011	625 387
<b>Total bank assets and</b>		<b>7 371 465</b>	<b>748 395</b>	<b>8 300 649</b>	<b>867 643</b>

### Capitals and creditors

Capital		3 057 419	310 407	3 057 419	319 583
Profit or loss		2 680 162	272 106	1 106 056	115 613
Outstanding debts		136 005	13 808	45 866	4 794
Other debts		567 260	57 592	333 859	34 897
Prepaid income	3	900 619	91 436	3 601 620	376 467
Prepaid costs, fees paid in adv.	4	30 000	3 046	155 830	16 288
<b>Total capital and creditors</b>		<b>7 371 465</b>	<b>748 395</b>	<b>8 300 649</b>	<b>867 643</b>

Notes		2017-01-01		2016-01-01	
		2017-12-31		2016-12-31	
		SEK	EUR	SEK	EUR
			9,8497		9,135

### Note 1 Outstanding claims

LED Pharma A/S		1 674	170	631 709	66 031
Israel Psoriasis Association		6 754	686		
<b>Total</b>		<b>8 428</b>	<b>856</b>	<b>1 905 029</b>	<b>199 127</b>



INTERNATIONAL FEDERATION  
OF PSORIASIS ASSOCIATIONS

17 (18)

<b>Note 2 Prepaid expenses and accrued income</b>				
Alviks Strand kontorshotell	95 968	9 743	61 034	6 380
Arén & Partner	837	85		
Länsförsäkringar	1 224	124		
Fortnox AB	2 021	205		
IFPA Invoice 3218 Serbia 2017	378	40		
IFPA Invoice 3220 Puerto Rico	220	22		
IFPA Invoice 3222 Slovakia 2017	495	50		
Accrued income Austria 2017	1 569	159		
Accrued income Vietnam 2017	395	40		
Accrued income Geroqia 2017	202	21		
Accrued income Argentina 2017	746	76		
Prepaid cost WPC	284 592	28 893		
<b>Total</b>	<b>388 647</b>	<b>39 459</b>	<b>406 226</b>	<b>42 462</b>
<b>Note 3 Prepaid income</b>				
LEO Pharma A/S	897 551	91 125	631 709	66 031
Psoriasis Association of Kenya	424	43	636	66
Israel Psoriasis Association	2 644	268		
<b>Total</b>	<b>900 619</b>	<b>91 436</b>	<b>3 601 620</b>	<b>376 467</b>
<b>Note 4 Prepaid costs and fees paid in advance</b>				
Hummelkläppen	30 000	3 046	30 000	3 136
<b>Total</b>	<b>30 000</b>	<b>3 046</b>	<b>30 000</b>	<b>3 136</b>



INTERNATIONAL FEDERATION  
OF PSORIASIS ASSOCIATIONS

18 (18)


**International Federation of Psoriasis Associations (IFPA)**  
Org. no 802428-5986

Stockholm 2018-06-27



---

Lars Ettarp  
President



---


Hoseah Waweru  
Vice President

---

Silvia Fernandez Barrio  
Secretary

---


Josef de Guzman  
Treasurer



---

Ingvar Ingvarsson  
Member at Large

Stockholm 2018-\_\_-\_\_  
2019-06-28



Tommy Nilsson  
Auktoriserad revisor



## Translation of Auditor's Report

To the meeting of the General Assembly of its Full members of International Federation of Psoriasis Associations

Corporate identity number 802428-5986

### Report on the annual accounts

#### *Opinions*

I have audited the annual accounts of International Federation of Psoriasis Associations for the financial year 2017.

In my opinion, the annual accounts have been prepared in accordance with the Annual Accounts Act and present fairly, in all material respects, the financial position of International Federation of Psoriasis Associations as of 31 december 2017 and its financial performance for the year then ended in accordance with the Annual Accounts Act. The statutory administration report is consistent with the other parts of the annual accounts.

I therefore recommend that the general meeting of members adopts the income statement and balance sheet.

#### *Basis for Opinions*

I conducted my audit in accordance with International Standards on Auditing (ISA) and generally accepted auditing standards in Sweden. My responsibilities under those standards are further described in the *Auditor's Responsibilities* section. I am independent of International Federation of Psoriasis Associations in accordance with professional ethics for accountants in Sweden and have otherwise fulfilled my ethical responsibilities in accordance with these requirements.

I believe that the audit evidence I have obtained is sufficient and appropriate to provide a basis for my opinions.

#### *Responsibilities of the Board of Directors*

The Board of Directors is responsible for the preparation of the annual accounts and that they give a fair presentation in accordance with the Annual Accounts Act. The Board of Directors is also responsible for such internal control as it determines is necessary to enable the preparation of annual accounts that are free from material misstatement, whether due to fraud or error.

In preparing the annual accounts, The Board of Directors is responsible for the assessment of the company's ability to continue as a going concern. It discloses, as applicable, matters related to going concern and using the going concern basis of accounting. The going concern basis of accounting is not applied if decision has been taken to discontinue the operations.

#### *Auditor's responsibility*

My objectives are to obtain reasonable assurance about whether the annual accounts as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes my opinions. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs and generally accepted auditing standards in Sweden will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these annual accounts.

As part of an audit in accordance with ISAs, I exercise professional judgment and maintain professional skepticism throughout the audit. I also:

- Identify and assess the risks of material misstatement of the annual accounts, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for my opinions. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.



- Obtain an understanding of the company's internal control relevant to my audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the company's internal control.

- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Board of Directors .

- Conclude on the appropriateness of the Board of Directors' use of the going concern basis of accounting in preparing the annual accounts. I also draw a conclusion, based on the audit evidence obtained, as to whether any material uncertainty exists related to events or conditions that may cast significant doubt on the company's ability to continue as a going concern. If I conclude that a material uncertainty exists, I am required to draw attention in my auditor's report to the related disclosures in the annual accounts or, if such disclosures are inadequate, to modify my opinion about the annual accounts. My conclusions are based on the audit evidence obtained up to the date of my auditor's report. However, future events or conditions may cause the company to cease to continue as a going concern.

- Evaluate the overall presentation, structure and content of the annual accounts, including the disclosures, and whether the annual accounts represent the underlying transactions and events in a manner that achieves fair presentation.

I must inform the Board of Directors of, among other matters, the planned scope and timing of the audit. I must also inform of significant audit findings during my audit, including any significant deficiencies in internal control that I identified.

## **Report on other legal and regulatory requirements**

### ***Opinions***

In addition to my audit of the annual accounts, I have also audited the administration of the Board of Directors of International Federation of Psoriasis Associations for the financial year 2017 and the proposed appropriations of the company's profit or loss.

I recommend to the general meeting of members that the loss be dealt with in accordance with the proposal in the statutory administration report and that the of the Board of Directors be discharged from liability for the financial year.

### ***Basis for Opinions***

I conducted the audit in accordance with generally accepted auditing standards in Sweden. My responsibilities under those standards are further described in the *Auditor's Responsibilities* section. I am independent of International Federation of Psoriasis Associations in accordance with professional ethics for accountants in Sweden and have otherwise fulfilled my ethical responsibilities in accordance with these requirements.

I believe that the audit evidence I have obtained is sufficient and appropriate to provide a basis for my opinions.

### ***Responsibilities of the Board of Directors***

The Board of Directors is responsible for the proposal for appropriations of the company's profit or loss. At the proposal of a dividend, this includes an assessment of whether the dividend is justifiable considering the requirements which the company's type of operations, size and risks place on the size of the company's equity, consolidation requirements, liquidity and position in general.

The Board of Directors is responsible for the company's organization and the administration of the company's affairs. This includes among other things continuous assessment of the company's financial situation and ensuring that the company's organization is designed so that the accounting, management of assets and the company's financial affairs otherwise are controlled in a reassuring manner.



***Auditor's responsibility***

My objective concerning the audit of the administration, and thereby my opinion about discharge from liability, is to obtain audit evidence to assess with a reasonable degree of assurance whether any member of the Board of Directors in any material respect:

- has undertaken any action or been guilty of any omission which can give rise to liability to the company, or
- in any other way has acted in contravention of the Companies Act, the Annual Accounts Act or the Articles of Association.

My objective concerning the audit of the proposed appropriations of the company's profit or loss, and thereby my opinion about this, is to assess with reasonable degree of assurance whether the proposal is in accordance with the Companies Act.

Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with generally accepted auditing standards in Sweden will always detect actions or omissions that can give rise to liability to the company, or that the proposed appropriations of the company's profit or loss are not in accordance with the Companies Act.

As part of an audit in accordance with generally accepted auditing standards in Sweden, I exercise professional judgment and maintain professional skepticism throughout the audit. The examination of the administration and the proposed appropriations of the company's profit or loss is based primarily on the audit of the accounts. Additional audit procedures performed are based on my professional judgment with starting point in risk and materiality. This means that I focus the examination on such actions, areas and relationships that are material for the operations and where deviations and violations would have particular importance for the company's situation. I examine and test decisions undertaken, support for decisions, actions taken and other circumstances that are relevant to my opinion concerning discharge from liability. As a basis for my opinion on the Board of Directors' proposed appropriations of the company's profit or loss I examined whether the proposal is in accordance with the Companies Act.

Stockholm

---

Tommy Nilsson  
Authorized Public Accountant